Cardiovascular diseases continue to be one of the leading causes of healthcare burden in India, and Glenmark has long been at the forefront of developing treatments to combat these life-threatening conditions. Over a decade ago, we entered the Indian market with a focused initiative on Cardiac and Anti-hypertensive treatments. Today, we offer a wide range of medications that help patients manage critical conditions such as Myocardial Infarction (MI), Angina, Heart Failure, and Hypertension.

Our flagship cardiovascular brand continues to be a market leader, providing patients with the medication they need to manage their heart conditions effectively. We also offer advanced combination therapies, including double and triple combinations, tailored for patients with uncontrolled hypertension requiring multiple medications. These therapies are designed to simplify treatment regimens, improving adherence and outcomes for patients.

Glenmark continues to show strong performance in the Indian cardiology market, holding the No. 5 position. This growth reflects not only the success of our products but also our commitment to ensuring that patients across India have access to the latest innovations in cardiovascular care. We remain focused on improving heart health and quality of life for millions of patients, helping them lead healthy lives.